Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model

Dilhan J. Perera¹,², Adam S. Hassan²,³, Yimei Jia⁴, Alessandra Ricciardi²,³, Michael J. McCluskie⁴, Risini D. Weeratna⁴ and Momar Ndao¹,²,³,⁵*

¹ Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada, ² Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³ Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada, ⁴ Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada, ⁵ National Reference Center for Parasitology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

Schistosomiasis threatens 800 million people worldwide. Chronic pathology manifests as hepatosplenomegaly, and intestinal schistosomiasis caused by Schistosoma mansoni can lead to liver fibrosis, cirrhosis, and blood in the stool. To assist the only FDA-approved drug, praziquantel, in parasite elimination, the development of a vaccine would be of high value. S. mansoni Cathepsin B (SmCB) is a well-documented vaccine target for intestinal schistosomiasis. Herein, we test the increased efficacy and immunogenicity of SmCB when combined with sulfated lactosyl archaeol (SLA) archaeosomes or AddaVax™ (a squalene based oil-in-water emulsion). Both vaccine formulations resulted in robust humoral and cell mediated immune responses. Impressively, both formulations were able to reduce parasite burden greater than 40% (WHO standard), with AddaVax™ reaching 86.8%. Additionally, SmCB with both adjuvants were able to reduce granuloma size and the amount of larval parasite hatched from feces, which would reduce transmission. Our data support SmCB as a target for S. mansoni vaccination; especially when used in an adjuvanted formulation.

Keywords: Schistosoma mansoni, schistosomiasis, vaccine, adjuvant, archaeosomes, AddaVax

INTRODUCTION

Schistosomiasis (Bilharzia) is an underestimated parasitic disease for which over 800 million people are at risk (1). This blood fluke spreads through fresh water in tropical and sub-tropical regions. Adult worms cause little to no pathology (2), however, female worms lay hundreds to thousands of eggs per day depending on the species of Schistosoma, some of which exit with the feces or urine, and others become trapped in host tissues causing chronic pathology.
Praziquantel (PZQ) used for the treatment of schistosomiasis has a reported efficacy of 86–93% (3, 4). However, it does not protect individuals from reinfection or remove pre-existing egg deposition. To aid the interruption of schistosomiasis a vaccine is pertinent (5). In the 1990s, independent testing of six candidate S. mansoni antigens underwent protective studies organized by a UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR/WHO) committee. Although these trials resulted in protection, the WHO goal of 40% or greater protection was not met, headlining the need for possible adjuvanted formulations (6).

S. mansoni Cathepsin B (SmCB) is the most abundant cysteine protease found in schistosomula and adult worm gut and somatic extracts. This protein is used for host blood molecule degradation and nutrient acquisition (7, 8). RNA interference studies demonstrate that when cathepsin B transcript levels are suppressed resulting worms show significant growth retardation compared to control parasites (9). By targeting cathepsin B, reduced egg fitness has been demonstrated by our group (10), and parasite anti-fecundity has also been seen in other flukes (11).

Our lab has exploited the immunogenic gut peptidase SmCB as a vaccine target, which reduces worm parasite burden by 59 and 60% when adjuvanted with CpG dinucleotides, and Montanide ISA 720 VG, respectively (12, 13). We believe that by combining a vaccine target, which reduces worm parasite burden by 59 and 60% when adjuvanted with CpG dinucleotides, and Montanide ISA 720 VG, respectively (12, 13). We believe that by combining this antigen with novel adjuvants, we will be able to increase parasite burden reduction and develop a more promising anti-schistosomiasis vaccine. Herein, we evaluate the immunogenicity and protective capability of our recombinant SmCB (rSmCB) adjuvanted by two additional adjuvants namely sulfated lactosyl archaeol (SLA) archaeosomes, and AddaVax™ (AddaVax).

METHODS

SmCB Recombinant Protein Preparation
S. mansoni Cathepsin B was prepared and purified as we previously described (12). Briefly, the PichiaPink™ system (Thermo Fisher Scientific, Waltham, MA, USA) was used, and recombinant yeast cells were cultured in a glycerol medium. After 3 days of growth, yeast cells were resuspended in a methanol induction medium to allow expression of recombinant protein. Recombinant protein purification was performed by Ni-NTA chromatography (Ni-NTA Superflow by QIAGEN, Venlo, Limburg, Netherlands). The eluted protein was analyzed by Western Blot using antibodies directed at the His-tag.

Immunization Protocol
Six to eight-week old female C57BL/6 mice were bred from mice obtained from Charles River Laboratories (Seneville, QC). Four groups of mice (n = 10–13) were immunized for humoral and cytokine assessment. Four groups of mice, (n = 10) were immunized and subsequently infected for parasite burden assessment. Group 1 (control): Mice were injected with phosphate-buffered saline (PBS) (Wisent Bioproducts, St. Bruno, QC). Group 2 (positive control): Mice were immunized with 20 μg of recombinant SmCB (rSmCB) and 35μl of Montanide ISA 720 VG (SEPPIC Inc., Fairfield, NJ). Group 3: Mice were immunized with 20 μg of rSmCB admixed with 1 mg of pre-formed empty SLA archaeosomes (NRC, Ottawa, Canada). Group 4: Mice were immunized with 20 μg of rSmCB and 25 μl of AddaVax™ (InvivoGen, San Diego, CA). Each mouse was immunized at weeks 0, 3, and 6 intramuscularly in the thigh with 50 μl of vaccine.

Schistosoma mansoni Challenge

Biomphalaria glabrata snails infected with the Puerto Rican strain of S. mansoni were provided by NIAID Schistosomiasis Resource Center of the Biomedical Research Institute (Rockville, MD). Three weeks after the final immunization mice were challenged with 150 cercariae via tail exposure for 1 h and sacrificed 7 weeks later for parasitological measures. Images of mouse livers were taken during dissection using a Galaxy S8 cell phone camera (Samsung Group, Seoul, South Korea). Adult worms were perfused from the hepatic portal system and counted manually (13). Liver sections were suspended in 10% buffered formalin phosphate (Fisher Scientific) and processed for histology as previously described (10). Remaining liver and intestines were weighed and digested overnight in 4% potassium hydroxide. The following day, the eggs present in these tissues were counted by microscopy and adjusted per gram of tissue. Burden reductions were calculated as previously described (12–14):

\[
\text{Percent of worms or eggs reduction} = \left(1 - \left(\frac{\text{mean number of worms or eggs recovered in immunized mice}}{\text{mean number of worms or eggs recovered in PBS control mice}}\right)\right) \times 100
\]

Serum Total SmCB-Specific IgG
SmCB-specific serum IgG was assessed by ELISA as described elsewhere (10). Briefly, high binding 96-well plates (Greiner Bio-One, Frickenhausen Germany) were coated with rSmCB (0.5 μg/ml) in 100 mM bicarbonate/carbonate buffer (pH 9.6) overnight at 4°C. After blocking plates with 2% bovine serum albumin (BSA; Sigma Aldrich) in PBS-Tween 20 (PBS-T: 0.05%; Fisher Scientific, Ottawa, ON, Canada) (blocking buffer), serum samples were added to the plates in duplicate. Plates were incubated for 1 h at 37°C then washed with PBS (pH 7.4) and horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Sigma Aldrich) was diluted 1:20,000 in blocking buffer and applied. Again, plates were washed with PBS, and 3,3',5,5'-tetramethyl benzidine (TMB) substrate (Millipore, Billerica, MA) was used for detection followed by the addition of H2SO4 (0.5M; Fisher Scientific). Optical density (OD) was measured at 450 nm with an EL800 microplate reader (BioTek Instruments Inc., Winooski, VT), and concentration of SmCB specific IgG was calculated by extrapolation from the IgG standard curve.

Serum SmCB-specific IgG1 and IgG2c
SmCB-specific serum IgG1, and IgG2c were assessed by ELISA as described elsewhere (10). Briefly, Immulon 2HB flat-bottom 96-well plates (Thermo Fisher) were coated with recombinant SmCB (0.5 μg/ml) in 100 mM bicarbonate/carbonate buffer (pH 9.6). The plates were washed with PBS-T, and blocking buffer was applied for 90 min. A serial dilution of serum was applied to plates in duplicate and incubated for 2 h at 37°C. Plates were washed again with PBS-T,
and goat anti-mouse IgG1-HRP (Southern Biotechnologies Associates, Birmingham, AL) or goat anti-mouse IgG2c-HRP (Southern Biotechnologies Associates) was applied to plates for 1 h at 37°C. After a final wash, TMB was added followed by H$_2$SO$_4$. Again, OD was measured as above. IgG1 and IgG2c endpoint titers were calculated as the reciprocal of the highest dilution, which gave a reading above the cut-off. The endpoint titer cut-off was statistically established as described elsewhere (15) using the sera of PBS immunized, unchallenged mice.

**Serum Total IgE**
Total IgE was assessed by ELISA using the BD OptEIA™ Set Mouse IgE Kit (BD, San Diego, CA) following manufacturer’s guidelines. Briefly, high binding 96-well plates (Grenier Bio-One) were coated with anti-mouse IgE capture antibody diluted in 100 mM bicarbonate/carbonate buffer (pH 9.6) 250-fold. Plates were again washed. Plates were washed and then blocked using PBS with 10% fetal bovine serum (Wisent Bio Products) for 1 h at room temperature. Plates were again washed. Samples were diluted in assay diluent then added to plates with standards and incubated for 2 h at room temperature. Plates were washed again, and biotinylated anti-mouse IgE antibody and streptavidin-horseradish peroxidase were added together for 1 h at room temperature. Plates were then washed a final time before TMB was added for 30 min protected from light. Lastly, 50 µl of H$_2$SO$_4$ was added to wells, and absorbance was read at 450 nm within 30 min.

**Cell-Mediated Immune Responses**
Three weeks after the last immunization, mice were sacrificed, spleens collected, and splenocytes isolated as previously described (16) with the following exceptions: splenocytes were resuspended in RPMI-1640 supplemented with 10% fetal bovine serum, 1 mM penicillin/streptomycin, 10 mM HEPES, 1X MEM non-essential amino acids, 1 mM sodium pyruvate, 1 mM L-glutamine (Wisent Bioproducts), and 0.05 mM 2-mercaptoethanol (Sigma Aldrich) (fancy RPMI, fRPMI). These cells were then used in the following assays:

**Proliferation Assay by BrdU**
Cell proliferation was measured by using the Roche chemiluminescent kit, following manufacturer’s guidelines. Splenocytes were seeded in black 96-well flat bottom plates at 200 000 cells per well. Each sample was seeded unstimulated, stimulated with rSmCB (2.5 µg/ml recombinant protein). After 72 h at 37°C + 5% CO$_2$ plates were centrifuged and supernatant collected and stored at -80°C until analysis. Cell supernatants were assessed for the presence of 16 cytokines and chemokines [IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17, IFNy, TNFa, CCL2 (MCP-1), CCL3 (MIP-1a), CSF2 (GM-CSF), and CCL5 (RANTES)] using Q-plex Mouse Cytokine–Screen (16-plex) multiplex ELISA following the manufacturer’s guidelines (Quansys Biosciences, Logan, UT, USA). Samples were run in singlet.

**Cytokine Production by Multiplex ELISA**
Splenocytes were incubated at 300 000 cells in 200 µl with rSmCB in fRPMI (2.5 µg/ml recombinant protein). After 72 h at 37°C + 5% CO$_2$, plates were centrifuged and supernatant collected and stored at -80°C until analysis. Cell supernatants were assessed for the presence of 16 cytokines and chemokines [IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17, IFNy, TNFa, CCL2 (MCP-1), CCL3 (MIP-1a), CSF2 (GM-CSF), and CCL5 (RANTES)] using Q-plex Mouse Cytokine–Screen (16-plex) multiplex ELISA following the manufacturer’s guidelines (Quansys Biosciences, Logan, UT, USA). Samples were run in singlet.

**Histology and Egg Granuloma Quantitation**
Liver sections in 10% buffered formalin phosphate were stained using hematoxylin and eosiin to assess granuloma size and egg
morphology. Granuloma area was measured using Zen Blue software (version 2.5.75.0; Zeiss) as previously reported (10, 18–21). Briefly, while working at 400x magnification, the pointer was used to trace the perimeter of 37–41 granulomas per experimental group with a clearly visible egg which the software converted into an area. Hepatic eggs were classified as abnormal if their internal structure was lost or the perimeter of the egg was crenelated. Fifteen different fields of vision were assessed per experimental group over two independent experiments. Abnormal eggs were counted and reported as a percent of the total eggs counted per field of vision.

**Miracidia Hatching Experiments**

Miracidia hatching was optimized and adapted from a protocol as described elsewhere (22). Briefly, one gram of feces from each experimental group was collected twice, one day before and at sacrifice 7 weeks post infection. Feces from each time point were assessed individually. Feces were resuspended in distilled water and transferred into an Erlenmeyer flask/conical tube. The flask/tube was then wrapped in tin foil to protect from light and was topped up with distilled water so that only 3 mm under the lid was exposed to light. Tin foil wrapped flasks were placed inside of a cardboard box, with a hole the same diameter as a lamp, through which light was shone on them for 3 h. After this time, water samples were collected from the exposed fraction of water and miracidia were counted. An image of the set up, and further detailed methodology can be seen in Supplemental Figure 2.

**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism 6 software (La Jolla, CA). Data were analyzed by Kruskal Wallis one-way ANOVA with Dunn’s multiple comparisons tests. Flow cytometry data were analyzed by a two-way ANOVA and Dunnett’s multiple comparisons tests. If present, outliers were calculated using GraphPad QuickCalcs and removed. P values < 0.05 were considered significant.

**RESULTS**

**Humoral Response to Vaccination**

No mice had detectable SmCB-specific IgG antibodies at baseline, and the PBS control remained negative throughout the study (Figure 1A). Mice receiving adjuvanted rSmCB developed SmCB-specific IgG after a single immunization. At week 3, groups adjuvanted with Montanide and AddaVax had significantly higher titers than with SLA, however this difference was no longer significant post first boost. Antigen specific IgG titers in vaccinated mice rose until week 6 before plateauing.

Endpoint titers were calculated for antigen specific IgG1 and IgG2c at the time of infection (Figure 1B). Each experimental group elicited a robust mixed IgG1/IgG2c response, although mice vaccinated with antigen and SLA or AddaVax had much higher IgG1 (3.84e6 ± 1.13e6 and 2.69e6 ± 9.24e5, respectively, than IgG2c titers (6.60e4 ± 3.21e4 and 7.88e4 ± 2.38e4, respectively). Mice immunized with rSmCB/Montanide had a balanced IgG1/IgG2c response with titers of 8.00e5 ± 1.09e5 and 2.03e5 ± 9.75e4, respectively. At this time, and at the second study endpoint (post-challenge) mouse serum was also analyzed for total IgE (Figure 1C).

At baseline, mice had little to no detectable IgE. In comparison to PBS controls, there was a greater increase in total IgE levels post immunization in groups receiving rSmCB adjuvanted with SLA (~3 fold) or AddaVax (~3.5 fold) than in the group immunized with...
rSmCB adjuvated with Montanide which saw no increase. Upon parasite challenge, the total IgE titers increased in all groups including the PBS controls with no significant differences between groups.

**Lymphoproliferation, Splenocyte Cytokine, and Chemokine Production in Response to Vaccination**

Enhanced SmCB-specific lymphoproliferation was seen in in ex vivo stimulated splenocytes from immunized compared to control mice. However, no statistical differences in the magnitude of lympho-proliferation was observed between immunized groups (Figure 2A). Differences in functionality of antigen-specific lymphocytes were further assessed by measuring cytokine and chemokine concentrations in culture supernatants.

For many of the cytokines and chemokines tested, adjuvanted formulations generated elevated levels above the PBS control (Supplemental Figure 3). However, differences can be seen in the cytokine milieu between experimental groups. The fold change expression of each cytokine/chemokine from the PBS control is depicted in a radar plot (Figure 2B) indicating each vaccine formulation favors a slightly different immune phenotype. Montanide has an increased Th17 immune profile, SLA an inflammatory, Th1, T-cell associated, and myeloid proliferating profile, and AddaVax a Th2 and anti-inflammatory profile.

**T-Cell Th1 Response to Vaccination**

Flow cytometry was used to enumerate splenic CD4+ and CD8+ T cell expression of IFNγ, IL-2, and TNFα in response to SmCB. Overall, an increase in cytokine expression was observed in CD4+ (Figure 3A) and CD8+ (Figure 3B) T cells in groups immunized with adjuvanted rSmCB over PBS controls. Mice immunized with rSmCB adjuvanted with SLA showed a significant increase in CD4+ IL-2 expression, whereas mice immunized with rSmCB adjuvanted with AddaVax showed a significant increase in CD4+ IL-2 and IFNγ expression compared to PBS control mice. All groups receiving adjuvanted rSmCB showed a significant increase in CD8+ IFNγ expression.

**Protection From Infection Upon Immunization With Adjuvanted rSmCB**

To determine the protective potential of the vaccines, a three-dose immunization regiment was tested. The average amount of worms collected from PBS control mice was 31 ± 7 worms over two independent experiments. Parasite burden reductions were calculated in reference to the PBS control mice within the same experiment to keep consistency within batches of infections. Parasite burden reductions were then combined and compared. All vaccine formulations significantly reduced parasite burden over PBS control with percent reduction in worm burden of 70.9 ± 3.9%, 60.5 ± 6.3%, and 86.8 ± 4.0% in groups adjuvanted with Montanide, SLA, and AddaVax, respectively.

![FIGURE 2](https://example.com/figure2.png)

**FIGURE 2** | Lymphoproliferation, cytokines, and chemokines. Splenocyte proliferation shown as stimulation index in response to rSmCB restimulation ex vivo (A). Means are shown with SEM. Significance is calculated against the PBS control. Mean levels of cytokine and chemokine expression were also reported as the fold change above the PBS control group and depicted in the radar plot in (B) with the axis in the natural log. Cytokines and chemokines have been grouped according to general functionality and labeled accordingly. Labels are colored reflecting the experimental group expressing the most amount of their cytokines/chemokines. n = 10 from two independent experiments. *P < 0.05, ***P < 0.001.
Pathology in schistosomiasis is caused by parasite eggs which become trapped in host tissues. Egg burdens in the liver (Figure 4B) and intestines (Figure 4C) were also calculated. Hepatic eggs in the PBS control group varied between 1250 and 14525 eggs/gram liver tissue. Similarly, intestinal eggs ranged between 1660 and 16973 eggs/gram intestine. rSmCB/Montanide reduced parasite burden by 70.3 ± 7.4% and 71.3 ± 8.4% in hepatic and intestinal eggs, respectively. The formulation of rSmCB/SLA reduced parasite burden by 49.8 ± 9.9% and 59.4 ± 8.8%, while rSmCB/AddaVax reduced parasite burden the most significantly, 78.0 ± 7.2% and 83.4 ± 6.6%, in hepatic and intestinal eggs, respectively.

Liver Pathology

During mouse dissection, images were taken of gross liver sections as pathology was clearly visible (Figure 5A). Livers from PBS control mice had many granulomas (visualized as white circular formations) that covered the surface of the liver due to heavy egg deposition, while vaccinated mice in all groups had less granuloma formation compared to PBS controls. By visual examination, mice immunized with rSmCB adjuvanted with Montanide or AddaVax had the least granuloma formation. Microscopic examination of liver tissue stained with hematoxylin and eosin stain (Figure 5B) revealed the presence of *S. mansoni* eggs within granulomatous formations. Granulomas were large, and well formed in PBS control mice, and eggs in granulomas were intact with normal appearances. Upon vaccination with adjuvanted rSmCB, granuloma sizes dropped from approximately 30,000 μm² to below 20,000 μm² (Figure 6A). Mean granuloma sizes in rSmCB formulated with Montanide and SLA were 17541 ± 1991 μm² and 16185 ± 2070 μm², respectively. Although granulomas were smallest in the group adjuvanted with AddaVax (13637 ± 1398 μm²) there were no statistical differences between vaccinated groups. Eggs in vaccinated animals were also abnormal in appearance (i.e., internal structure was lost or compromised, edges were crenellated and incomplete) (Figure 6B). A percentage of 47.7 ± 9.5% eggs were found to be abnormal in mice immunized with rSmCB/Montanide. When rSmCB was adjuvanted with SLA and AddaVax, 39.9 ± 7.0% and 42.9 ± 5.3% of eggs were found to be abnormal, again differences between vaccinated groups were not significant.

Egg Hatching

To assess whether our vaccine formulations could interrupt the transmission of schistosomiasis we tested whether eggs retrieved from feces were able to give rise to larvae. Feces from PBS control mice gave rise to 76.3 ± 10.0 miracidia (Figure 7). Feces from experimental groups saw significant reductions in miracidia: 15.4 ± 0.4, 36.2 ± 3.7, and 13.6 ± 1.7 miracidia hatched from Montanide, SLA, and AddaVax groups, respectively, with no statistical significance between them.

**DISCUSSION**

Our group has previously shown the protective capabilities of SmCB, when adjuvanted with CpG dinucleotides (12) and Montanide ISA 720 VG (13). In this work we evaluated the protective capabilities of two new adjuvants: sulfated lactosyl archaeol (SLA) archaeosomes and AddaVax, a squalene-based oil-in-water emulsion similar to MF59. When used as an adjuvant, SLA has been shown to activate strong humoral and cell-mediated responses against multiple antigens by increasing local cytokine production, immune cell trafficking, and antigen uptake at the injection site, leading to increased protection in murine models of infectious disease and cancer (23–25). In this study, we used a novel admixed formulation which provides a simple ready to mix adjuvant formulation with no loss of antigen during the formulation process (26). AddaVax alternatively, is a squalene-oil based emulsion structurally similar to MF59, which
acts by stimulating local cytokine and chemokine production, attracting immune cells to the injection site and increasing antigen trafficking and presentation (27).

SmCB, is a gut cysteine peptidase necessary for parasite growth and maturity. Although immunogenic and capable of protecting from *S. mansoni* infection when used alone (28), our laboratory has shown that adjuvants enhance its immunogenicity and protective efficacy (12, 13, 29), the highest protection seen with Montanide (13).

In a series of preliminary studies, we tested a variety of other adjuvant formulations (including: AddaVax, aluminum hydroxide (alum), alum/CpG dinucleotides, alum/monophosphoryl lipid A, and SLA, alongside Montanide and PBS as controls) in combination with rSmCB for immunogenicity and protection from parasite challenge, to determine the most efficacious (Supplemental Figure 4). Of the adjuvant formulations tested, the most significant impact on reducing the parasite burden was seen when rSmCB was adjuvanted with SLA or AddaVax. Therefore, the present study was conducted to further elucidate the immune mechanisms behind this protection. The two adjuvanted formulations in this study were able to surpass the WHO schistosomiasis vaccine threshold of 40% protection (6), similar to our previous efforts. SLA reduced adult worms, liver eggs, and intestinal eggs by 60.5, 49.8, and 59.4%, respectively, while AddaVax reached 86.8, 78.0, and 83.4% in the same readouts (Figure 4).

Eggs trapped in host tissues release soluble egg antigens triggering granuloma formation, leading to liver cirrhosis and other fatal morbidities (30). Both emulsion-based vaccines (Montanide and AddaVax) were able to visibly reduce granuloma size, and parasite pathology to the liver (Figure 5). Granuloma formation is initiated by Th2 immune responses; however, when mice mount extreme Th1 polarization responses, liver pathology is severe (31). This was shown in mice immunized with schistosome egg antigens (SEA) and complete Freunds adjuvant (32), and again in mice that lack both IL-10 and IL-4, which reached 100% mortality upon infection with schistosomiasis (33). Although SmCB is not expressed by eggs trapped in host tissue, it is a secreted protein of *S. mansoni* adult flukes which reside in venules in and around the liver and intestines. It is possible that SmCB specifically lymphocyte reactivation is causing the expression of Th1 and inflammatory cytokines that are indirectly contributing to the deleterious liver pathology seen in SLA vaccinated animals. Despite a greater number of eggs found in SLA liver tissues than Montanide and AddaVax, granulomas around these eggs were equally reduced in size.

Eggs released in feces into freshwater, will hatch miracidia, the first larval stage of the parasite. To our knowledge, we are the first group to test *S. mansoni* vaccine efficacy in reducing hatched parasite from fecal samples, although others have demonstrated hatching from liver deposited eggs (34, 35). We found that one gram of feces led to a reduced number of hatched miracidia in animals vaccinated with rSmCB and Montanide or AddaVax. As shown in previous work (9, 36), targeting a digestive enzyme may lead to a suppression of metabolic activities necessary for proper reproduction, leading to the lowered fertility and egg fitness demonstrated by our vaccines. Despite the fact that our results do not account for the variability in fecal egg shedding from day-to-day (37, 38), we believe the reduction in hatched...
The parasite observed in vaccinated animals would mean reduced schistosomiasis transmission.

Immunogenicity studies suggest that the protection mediated by our vaccine formulations could be explained by a robust humoral and cellular mediated immunity (CMI), and it is likely that both these responses contribute to protection from schistosomiasis.

Several groups have shown a positive correlation between IgG antibody titer and protection from schistosomiasis suggesting a necessity for the humoral response. This response was seen to mediate antibody mediated cellular cytotoxicity (ADCC) and activate complement as an attack against schistosomula (29, 39, 40) in vitro. By this mechanism or due to another, high IgG titers have been found in vaccinated animals with reduced adult worm burdens. Interestingly, a study in rhesus macaques not only showed a reduction in worm burden correlated to IgG, but collected worms were morphologically stunted with degenerated reproductive systems (41). As our vaccine formulations produced robust IgG titers, they all showed promise for a protective vaccine. Learning from the failed hookworm vaccine (42), we wanted to ensure our vaccine formulations did not cause IgE hypersensitivity, as IgE is a trademark of helminth infections like Schistosoma mansoni (43). We saw slight increases in total IgG levels after immunization using SLA and AddaVax which were not present in Montanide adjuvanted groups or the PBS control. However, post challenge, total IgG levels were similar in all groups including unvaccinated controls (Figure 1C). Thus, detrimental effects associated with vaccine induced IgE responses are unlikely.

Ex vivo re-stimulation of splenocytes with rSmCB showed significant lymphoproliferation in all vaccinated groups, so we were curious to see what cell mediated immunity was being elicited by our different vaccines. Although all vaccine groups increased cytokine expression, there were subtle differences in their cytokine milieu between different adjuvant formulations (Figure 2B). When combined with SLA, SmCB was broadly stimulating increasing inflammatory cytokines, Th1 and T-cell associated cytokines, as well as the myeloid proliferation cytokine IL-3, whereas with Montanide and AddaVax, SmCB led to increased Th17, and Th2/Anti-inflammatory cytokines, respectively.

From the creation of the S. mansoni radiation-attenuated cercaria vaccine, it has been the consensus that IFNγ and TNFα play pivotal roles in protection (44–46). It is a promising feature that when CD4+ and CD8+ T cells from vaccinated animals were stimulated ex vivo with rSmCB we observed increases of IFNγ, with trends of increased TNFα. Although the percentage increases observed are small, the number of cells that they represent specific to our antigen is significant. Interestingly, our multiplex ELISA data show significant production of IFNγ by all vaccinated groups, which is not fully reflected in our T cell expression as seen by flow cytometry. Future studies could prove useful to identify which other cell types are contributing to IFNγ expression, especially for mice vaccinated with Montanide and SLA.

As previously mentioned, both SLA and AddaVax have been shown to activate the immune system (23–25, 27) and it is due to this quality that they have been exploited as vaccine adjuvants. This study sought to assess the increased efficacy of SmCB when combined with these compounds, however further studies should be conducted to elucidate the possible protective effects of the adjuvants themselves in schistosomiasis infection.

Adjuvanting schistosomiasis vaccines is not a new concept. Previous work has shown 70% reduction in worm burden with a Sm-p80 tegument vaccine administered by DNA prime and boosted with protein and oligodeoxydinucleotides (47), and 57% reduction in worm burden with a Sm-Tsp-2 tetraspanin vaccine adjuvanted with Freund’s incomplete adjuvant (48), among others. However, to our knowledge, we are the only group to test SLA archaeosomes and AddaVax in the presence of SmCB and are reducing adult worm burden the most significantly of all the recombinant protein vaccines in pre-clinical trials. Our data support the hypothesis that Schistosoma mansoni Cathepsin B is a strong candidate for an anti-schistosome vaccine and can be readily formulated with multiple different types of adjuvants including oil-in-water and
water-in-oil emulsions, archaeosomes and TLR9 agonists. Future directions include conducting dose response experiments on tested adjuvants, as a single dose level of SLA was tested, and AddaVax was formulated as per the manufacturer’s guidelines. Additionally, it would be useful to conduct more in-depth immunological and mechanistic studies to further elucidate the correlates of protection being elicited by our vaccines.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Facility Animal Care Committee of the Research Institute of the McGill University Health Center (Animal Use Protocol 7625).

AUTHOR CONTRIBUTIONS

Experimental design was conducted by DP and MN in collaboration with YJ, RW, and MM. AR provided the initial protocols needed for protein expression. Experiments were conducted by DP and AH assisted with animal sacrifice. The manuscript was prepared by DP and MN, with revisions by YJ, RW, and MM. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants provided by the Public Health Agency of Canada and the Foundation of the McGill University Health Center.
ACKNOWLEDGMENTS

We thank Annie Beauchamp for her assistance with animal work, Lydia Labrie, and Francesca Fargnoli for assistance with sample collection and processing, andStephane Pillet and Hilary Hendin for their contributions to our flow cytometry panel. We would also like to thank Dr. Margaret Mentink-Kane and Kenia V. Benitez from the Biomedical Research Institute (Rockville, MD) for supplying us with infected Biomphalaria snails, as well as the Immunophenotyping and Histopathology cores at the Research Institute of the McGill University Health Center (RI-MUHC) (Montreal, QC). Last, we would like to thank Lise Deschatelets, Vandana Chandan, Janelle Sauvageau, Dean Williams, Mohammad P Jamshidi, Lakshmi Krishnan, and all of our other collaborators at the National Research Council of Canada (Ottawa, ON) for their continued support. The National Reference Centre for Parasitology is supported by Public Health Agency of Canada/National Microbiology Laboratory, the Foundation of the Montreal General Hospital, the Foundation of the McGill University Health Centre and the Research Institute of the McGill University Health Centre.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.605288/full#supplementary-material
26. Jia Y, Akache B, Deshatelets L, Qian H, Dudani R, Harrison BA, et al. A comparison of the immune responses induced by antigens in three different arcahsoas-based vaccine formulations. Int J Pharm (2019) 561:187-96. doi: 10.1016/j.ijpharm.2019.02.041

27. O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - An innately attractive adjuvant formulation. Vaccine (2012) 30:4341-8. doi: 10.1016/j.vaccine.2011.09.061

28. Tallima H, Dvorak J, Karem S, El Dahab MA, Aziz NA, Dalton JP, et al. Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase. Fujiwara RT, editor. PLoS Negl Trop Dis (2017) 11(3):e005443. doi: 10.1371/journal.pntd.005443

29. Ricciardi A, Zelt NH, Visitsunthorn K, Dalton JP, Ndao M. Immune mechanisms involved in schistosoma mansoni-Cathepsin B vaccine induced protection in mice. Front Immunol (2018) 9[JUL]:1710. doi: 10.3389/fimmu.2018.01710

30. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Prim (2018) 4(1):13. doi: 10.1038/s41572-018-0013-8

31. La Flame AC, Patton EA, Pearce EJ. Role of gamma interferon in the pathogenesis of severe Schistosomiasis in interleukin-4-deficient mice. Infect Immun (2001) 69(12):7445–52. doi: 10.1128/IAI.69.12.7445-7452.2001

32. Ruitzsky LI, Hernandez HJ, Stadecker MJ. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosoma infection. Proc Natl Acad Sci U S A (2001) 98(23):13243–8. doi: 10.1073/pnas.231258498

33. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the Dangers of Immune Interference of Schistosoma mansoni cathepsin D, the apical enzyme of the hemoglobin proteolysis cascade. J Immunol (2000) 164(12):6406–16. doi: 10.4049/jimmunol.164.12.6406

34. Tedla BA, Pickering D, Becker L, Loukas A, Pearson MS. Vaccination with Schistosoma mansoni cholinesterases reduces the parasite burden and egg viability in a mouse model of schistosomiasis. Vaccines (2020) 8(2):162. doi: 10.3390/vaccines8020162

35. Le L, Molehin AJ, Nash S, Sennoune SR, Ahmad G, Torben W, et al. Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. Pathology (2018) 91(4):442–9. doi: 10.1016/j.pathol.2018.01.004

36. Morales ME, Rivalent G, Gobert GN, Kines KJ, Tort JB, Brindley PJ. RNA interference of Schistosida mansoni cathpsin D, the apical enzyme of the hemoglobin proteolysis cascade. Mol Biochem Parasitol (2008) 157(2):160–8. doi: 10.1016/j.molbiopara.2007.10.009

37. Engels D, Sinzinkayo E, De Vlas SJ, Gryseels B. Intraspecimen fecal egg count variation in Schistosoma mansoni infection. Am J Trop Med Hyg (1997) 57(5):571–7. doi: 10.4269/ajtmh.1997.57.571

38. Degarre A, Legesse M, Medhin G, Teklehaimanot T, Erko B. Day-to-day fluctuation of point-of-care circulating cathodic antigen test scores and faecal egg counts in children infected with Schistosoma mansoni in Ethiopia. BMC Infect Dis (2014) 14(1):210. doi: 10.1186/1471-2334-14-210

39. Ramalho-Pinto FJ, De Rossi R, Smithers SR. Murine Schistosomiasis mansoni: anti-schistosomula antibodies and the IgG subclasses involved in the complement- and eosinophil-mediated killing of schistosomula in vitro. Parasite Immunol (1979) 1(4):295–308. doi: 10.1111/j.1365-3024.1979.tb00715.x

40. Khalife J, Dunne DW, Richardson BA, Mazza A, Thorne KJ, Capron A, et al. Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni. J Immunol (1989) 142(12):4422–7. doi: 0022-1767/89/14212-4422S02.00/0

41. Wilson RA, Langermans JAM, van Dam GJ, Vervenne RA, Hall SL, Borges WC, et al. Elimination of Schistosoma mansoni Adult Worms by Rhesus Macaques: Basis for a Therapeutic Vaccine? Bethony J, editor. PLoS Negl Trop Dis (2008) 2(9):e290. doi: 10.1371/journal.pntd.0000290

42. Diemert D, Pinto A, Freire [A-J of A and 2012 undefined. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. United States: Elsevier (2012). Available at: https://www.sciencedirect.com/science/article/pii/S0091674912007026.

43. Maizels RM, McSorley HJ. Regulation of the host immune system by helminth parasites. J Allergy Clin Immunol (2016) 138(3):666–75. doi: 10.1016/j.jaci.2016.07.007

44. Wilson RA, Coulson PS. Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite’s armour. Trends Parasitol (2009) 25:423–31. doi: 10.1016/j.pt.2009.05.011

45. Wilson RA, Coulson PS, Mountford AP. Immune responses to the radiation-attenuated schistosome vaccine: What can we learn from knock-out mice? Immunol Lett (1999) 65:117–23. doi: 10.1016/S0165-2478(99)00134-5

46. Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol (2005) 27:271–80. doi: 10.1111/j.1365-3045.2005.00764.x

47. Ahmad G, Zhang W, Torben W, Haskins C, Digs S, Noor Z, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res (2009) 105(6):1767–77. doi: 10.1007/s00436-009-1646-z

48. Pearson MS, Pickering DA, McSorley HJ, Bethony JM, Tribololet L, Dougall AM, et al. Enhanced Protective Efficacy of a Chimeric Form of the Schistosoma Vaccine Antigen Sm-TSP-2. Hirayama K, editor. PLoS Negl Trop Dis (2012) 6(3):e1564. doi: 10.1371/journal.pntd.0001564

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.